

**Anti-ICOS / CD278 Reference Antibody (feladilimab)  
Recombinant Antibody  
Catalog # APR10123**

**Specification**

---

**Anti-ICOS / CD278 Reference Antibody (feladilimab) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">O9Y6W8</a>
Reactivity	Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG4PE
Calculated MW	145.52 KDa

**Anti-ICOS / CD278 Reference Antibody (feladilimab) - Additional Information**

**Target/Specificity**  
ICOS / CD278

**Endotoxin**  
< 0.001EU/ µg,determined by LAL method.

**Conjugation**  
Unconjugated

**Expression system**  
CHO Cell

**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

**Storage**  
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.

**Anti-ICOS / CD278 Reference Antibody (feladilimab) - Protein Information**

**Name** ICOS

**Synonyms** ALLIM

**Function**  
Enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells. Essential both for efficient interaction between T and B-cells and for normal antibody responses to T-cell dependent antigens. Does not up-regulate the production of interleukin- 2, but superinduces the synthesis of interleukin-10. Prevents the apoptosis of pre-activated T-cells. Plays a critical role in CD40- mediated class switching of immunoglobulin

isotypes (By similarity).

### Cellular Location

[Isoform 1]: Cell membrane; Single-pass type I membrane protein

### Tissue Location


Activated T-cells. Highly expressed on tonsillar T-cells, which are closely associated with B-cells in the apical light zone of germinal centers, the site of terminal B-cell maturation. Expressed at lower levels in thymus, lung, lymph node and peripheral blood leukocytes. Expressed in the medulla of fetal and newborn thymus.

## Anti-ICOS / CD278 Reference Antibody (feladilimab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


## Anti-ICOS / CD278 Reference Antibody (feladilimab) - Images



Anti-ICOS / CD278 Reference Antibody (feladilimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.



The purity of Anti-ICOS / CD278 Reference Antibody (feladilimab) is more than 99.12%, determined by SEC-HPLC.



Immobilized human ICOS FC at 2 µg/mL can bind Anti-ICOS / CD278 Reference Antibody (feladilimab)  $EC_{50}=0.09127$  µg/mL